As of Jul 02
| -0.04 / -1.98%|
The 5 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 4.50, with a high estimate of 8.00 and a low estimate of 3.50. The median estimate represents a +127.27% increase from the last price of 1.98.
The current consensus among 5 polled investment analysts is to Buy stock in CTi Biopharma Corp. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.